New study peers inside the brain after a stroke to uncover healing clues
NCT ID NCT07583147
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 117 people who had a brain bleed (intracerebral hemorrhage) to understand how inflammation and damage to the brain's protective barrier affect recovery. Participants will get special brain scans and blood tests about 10 days after the bleed. The goal is to link these findings to how well they recover 6 months later, which could guide future treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 117 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adults (≥ 18 years old); 2. presenting with a symptomatic spontaneous supratentorial ICH; 3. ICH within 48 hours after symptoms onset (or last seen well); 4. ICH confirmed by brain imaging; 5. Informed consent documented; 6. Affiliated or beneficiary of social security scheme. Exclusion Criteria: 1. Massive ICH volume (≥ 60 ml) at admission; 2. Severe coma (defined as a Glasgow Coma Scale score \< 6) at admission; 3. Planned neurosurgical hematoma evacuation; 4. Decision already taken for palliative care with withdrawal of active treatment; 5. Pre-existing dependance defined as a mRS score ≥2 prior to ICH occurrence; 6. Underlying secondary cause of ICH including macrovascular causes (brain arteriovenous malformation, intracranial aneurysm, dural arteriovenous fistula, cavernous malformation), brain tumour, cerebral venous thrombosis, hemorrhagic infarction. Patients taking oral anticoagulant can be included; 7. TSPO genotyping demonstrating a low affinity binder profile, 8. Unable to tolerate or contraindicated to brain MRI: medical material not MRI compatible, claustrophobia, known hypersensitivity to gadoteric acid, meglumin or any drug containing gadolinium; 9. Estimated glomerular filtration rate \< 30 ml/min/1.73 m 2 10. Unable to tolerate or contraindicated to 18F-DPA714 PET: women who are pregnant or breastfeeding, claustrophobia, and known hypersensitivity to DPA-714; 11. Use of Benzodiazepines within 7 days (within 6 weeks for prazepam, diazepam or clorazepate) preceding TSPO PET acquisition; 12. Co-existing neuroinflammatory disease such as Multiple Sclerosis, Neuromyelitis optica, Neurosarcoidosis, autoimmune encephalitis, CNS vasculitis; 13. Conditions requiring long-term immunosuppressive medication; 14. Expected impossible follow-up or poor compliance; 15. Patient under tutorship, curatorship, or legal protection.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Intracerebral hemorrhage are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU de Bordeaux
Bordeaux, 33000, France
-
CHU de Toulouse
Toulouse, 31000, France
-
CHU de montpellier
Montpellier, 34000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a web program rebuild memory after brain injury?
- Portable MRI could speed up stroke treatment
- Can a herbal formula match traditional medicine for brain bleeds?
- Can a blood marker tell fever from infection in stroke?
- Can blood markers predict brain injury outcomes?
- Can an ancient herbal pill improve outcomes after a bleeding stroke?